Bioelectron Technology Corporation
Records under this name other than patents Bioelectron Technology Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Bioelectron Technology Corporation
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,519,001 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,169,196 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,546,132 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,167,251 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,968,166 | 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,840,497 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,968,746 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,653,144 | Treatment of pervasive developmental disorders with redox-active therapeutics Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,399,612 | Treatment of pervasive developmental disorders with redox-active therapeutics Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,105,325 | Treatment of pervasive developmental disorders with redox-active therapeutics Formerly held In force · From the USPTO record | In force | From the USPTO record |